Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KR24258
- Development stage
- Preclinical
- Lead developer
- Jiangxi Kvvit Pharmaceutical
01
Overview
KR24258 is a preclinical drug candidate currently under development by Jiangxi Kvvit Pharmaceutical (also known as Qingfeng Pharmaceutical Group). As of the latest pipeline updates, the drug is in the preclinical (PCC) stage. Publicly available information regarding its specific biological target, therapeutic modality, and primary disease indication remains limited, although it is categorized within the company's broader research efforts which include oncology, infectious diseases, and central nervous system (CNS) disorders.
Beyond the preview
Go deeper on KR24258.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KR24258.